SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
December 20, 2001
Date of Report (Date of earliest event reported)
--------------------
NEOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-28782 93-0979187
(State or other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification Number)
157 TECHNOLOGY DRIVE 92618
IRVINE, CALIFORNIA (Zip Code)
(Address of principal executive offices)
(949) 788-6700
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
On December 20, 2001, NeoTherapeutics, Inc. issued a news release announcing
that it's subsidiary, NeoGene Technologies, entered into a second license
agreement with Pfizer Inc. for the use of an orphan receptor identified by
NeoGene. The text of the press release is set forth in Exhibit 99.1 attached to
this report and incorporated herein by this reference.
ITEM 7. EXHIBITS
Exhibits:
99.1 Press Release dated December 20, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NEOTHERAPEUTICS, INC.
Date: December 20, 2001 By: /s/ Samuel Gulko
--------------------------
Name: Samuel Gulko
Title: Senior Vice President, Finance,
Chief Financial Officer, Secretary
and Treasurer
Exhibit
Number Document Description
------ --------------------
99.1 Press Release dated December 20, 2001.